Clovis Oncology, Inc.: M&A transaction — Clovis Oncology completes sale of FAP-2286 to Novartis amid Chapter 11

Clovis Oncology, Inc.

Sale of pipeline targeted radionuclide therapy program FAP-2286 closed April 14, 2023.
Court approved the transaction on March 21, 2023; sale includes in-licensing agreement with 3B Pharmaceuticals.
Company expects no payment to common stockholders given senior debt and contingent milestones.

item 2.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Clovis Oncology, Inc. completed a disposition involving Novartis Innovative Therapies AG (closed 2023-04-14).

Action: disposition
Counterparty: Novartis Innovative Therapies AG
Closing: 2023-04-14

Exact text from the filing

On April 14, 2023, the Company and Novartis consummated the FAP Sale Transaction.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-23-101292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.